VIVS Stock Summary and Trading Ideas (Vivosim Labs | NASDAQ:VIVS)

VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.

Vivosim Labs trades on the NASDAQ stock market under the symbol VIVS.

As of July 31, 2026, VIVS stock price declined to $0.34 with 2,683,961 million shares trading.

VIVS has a beta of 2.49, meaning it tends to be more sensitive to market movements. VIVS has a correlation of 0.07 to the broad based SPY ETF.

VIVS has a market cap of $1.20 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that VIVS belongs to (by Net Assets): VXF.

VIVS has underperformed the market in the last year with a price return of -81.6% while the SPY ETF gained +19.4%. VIVS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -75.9% and -40.5%, respectively, while the SPY returned +4.2% and +0.5%, respectively.

VIVS support price is $.34 and resistance is $.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VIVS shares will trade within this expected range on the day.